Potential beneficial metabolic interactions between tamoxifen and isoflavones via cytochrome P450-mediated pathways in female rat liver microsomes

Pharmaceutical Research

Volumn 21, Issue 11, 2004, Pages 2095-2104

  Chen, Jun ^a   Halls, Steven C ^a   Alfaro, Joshua F ^a   Zhou, Zhaohui ^a   Hu, Ming ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Cytochrome P450; Drug interaction; Genistein; Rat liver microsomes; Tamoxifen

Indexed keywords

ALPHA NAPHTHOFLAVONE; BIOCHANIN A; CYTOCHROME; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C6; CYTOCHROME P450 2D1; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; DAIDZEIN; DIETHYLDITHIOCARBAMIC ACID; DRUG METABOLITE; ENZYME INHIBITOR; FORMONONETIN; GENISTEIN; GLYCITEIN; INDOMETACIN; ISOFLAVONE DERIVATIVE; KETOCONAZOLE; MEVINOLIN; PROADIFEN; QUERCETIN; QUINIDINE; SULFAPHENAZOLE; TAMOXIFEN; TRANYLCYPROMINE; TROLEANDOMYCIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; FEMALE; HYDROXYLATION; IN VITRO STUDY; INCUBATION TIME; KINETICS; LIVER MICROSOME; METHYLATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STANDARD; ALGORITHM; ANIMAL; DRUG ANTAGONISM; DRUG INTERACTION; ENZYMOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; SPRAGUE DAWLEY RAT;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GENISTEIN; ISOFLAVONES; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN;

EID: 21644485502     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000048202.92930.61     Document Type: Article

References (49)

1. V. C. Jordan, S. Gapstur, and M. Morrow. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J. Natl. Cancer Inst. 93: 1449-1457 (2001).
2. J. L Perez-Gracia and E. M Carrasco. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol. Oncol. 84:201-209 (2002).
3. R. C Bergan, E. Reed, C. E Myers, D. Headlee, O. Brawley, H. K. Cho, W. D. Figg, A. Tompkins, W. M. Linehan, D. Kohler, S. M Steinberg, and M. V. Blagosklonny. A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 5:2366-2373 (1999).
4. E. Pukkala, P. Kyyronen, R. Sankila, and K. Holly. Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study. Int. J. Cancer 100:337-341 (2002).
5. S. Shibutani, A. Ravindernath, N. Suzuki, I. Terashima, and S. M. Sugarman. A. P Grollman, M. L. Pearl. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 21:1461-1467 (2000).
6. D. H. Phillips. Understanding the genotoxicity of tamoxifen? Carcinogenesis 22:839-849 (2001).
7. I. N. White. Anti-oestrogenic drugs and endometrial cancers. Toxicol. Lett. 120:21-29 (2001).
8. A. Umemoto, K. Komaki, Y. Monden, M. Suwa, Y. Kanno, M. Kitagawa, M. Suzuki, C. X. Lin, Y. Ueyama, M. A. Momen, A. Ravindernath, and S. Shibutani. Identification and quantification of tamoxifen-DNA adducts in the liver of rats and mice. Chem. Res. Toxicol 14:1006-1013 (2001).
9. S. Shibutani, P. M. Shaw, N. Suzuki, L. Dasaradhi, M. W. Duffel, and I. Terashima. Sulfation of alpha-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts. Carcinogenesis 19:2007-2011 (1998).
10. G. Milano, M. C. Etienne, M. Frenay, R. Khater, J. L. Formento, N. Renee, J. L. Moll, M. Francoual, M. Berto, and M. Namer. Optimized analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumors. Br. J. Cancer 55:509-512 (1987).
11. R. R. Reddel, L. C. Murphy, and R. L. Sutherland. Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro. Cancer Res. 43:4618-4624 (1983).
12. S. M. Langan-Fahey, D. C. Tormey, and V. C. Jordan. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur. J. Cancer 26:883-888 (1990).
13. G. K. Poon, Y. C. Chui, R. McCague, P. E. Linning, R. Feng, M. G. Rowlands, and M. Jarman. Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab. Dispos. 21:1119-1124 (1993).
14. C. Mani, H. V. Gelboin, S. S. Park, R. Pearce, A. Parkinson, and D. Kupfer. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21:645-656 (1993a).
15. C. Mani, E. Hodgson, and D. Kupfer. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21:657-661 (1993b).
16. D. J. Boocock, J. L. Maggs, I. N. White, and B. K. Park. α-hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro. Carcinogenesis 20:153-160 (1999).
17. H. K. Crewe, L. M. Notley, R. M. Wunsch, M. S. Lennard, and E. M. Gillam. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos. 30:869-874 (2002).
18. M. Kurzer and X. Xu. Dietary Phytoestrogens. Annu. Rev. Nutr. 17:353-381 (1997).
19. D. F. Birt, S. Hendrich, and W. Wang. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol. Ther. 90:157-177 (2001).
20. C. S. Yang, J. M. Landau, M. T. Huang, and H. L. Newmark. Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu. Rev. Nutr. 21:381-406 (2001).
21. H. Wiseman. The therapeutic potential of phytoestrogens. Expert Opin. Investig. Drugs 9:1829-1840 (2000).
22. Y. Liu and M. Hu. Absorption and metabolism of flavonoids in the Caco-2 cell culture model and a perfused rat intestinal model. Drug Metab. Dispos. 30:370-377 (2002).
23. J. Chen, H. Lin, and M. Hu. Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J. Pharmacol. Exp. Therap 304:1228-1235 (2003).
24. K. D. Setchell, N. M. Brown, P. Desai, L. Zimmer-Nechemias, B. E. Wolfe, W. T. Brashear, A. S. Kirschner, A. Cassidy, and J. E. Heubi. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J. Nutr. 131:1362S-1375S (2001).
25. M. Hu, K. Krausz, J. Chen, X. Ge, J. Q. Li, H. L. Gelboinl, and F. J. Gonzalez. Identification of CYP1A2 the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab. Dispos. 31:924-931 (2003).
26. S. E. Kulling, D. M. Honig, and M. Metzler. Oxidative metabolism of the soy isoflavones daidzein and genistein in humans in vitro and in vivo. J. Agric. Food Chem. 49:3024-3033 (2001).
27. E. S. Roberts-Kirchhoff, J. R. Crowley, P. F. Hollenberg, and H. Kim. Metabolism of genistein by rat and human cytochrome P450s. Chem. Res. Toxicol. 12:610-616 (1999).
28. S. E. Kulling, D. M. Honig, T. J. Simat, and M. Metzler. Oxidative in vitro metabolism of the soy phytoestrogens daidzein and genistein. J. Agric. Food Chem. 48:4963-4972 (2000).
29. K. M. Newton, D. S. Buist, N. L. Keenan, L. A. Anderson, and A. Z. LaCroix. Use of alternative therapies for menopause symptoms: results of a population-based survey. Obstet. Gynecol. 100:18-25 (2002).
30. M. J. Messina and C. L. Loprinzi. Soy for breast cancer survivors: a critical review of the literature. J. Nutr. 131:3095S-3108S (2001).
31. A. Brzezinski and A. Debi. Phytoestrogens: the "natural" selective estrogen receptor modulators? Eur. J. Obstet. Gynecol. Reprod. Biol. 85:47-51 (1999).
32. D. Carusi. Phytoestrogens as hormone replacement therapy: an evidence-based approach. Care Update Ob. Gyns 7:253-259 (2000).
33. F. Shen, X. Xue, and G. Weber. Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells. Anticancer Res. 19:1657-1662 (1999).
34. V. Tanos, A. Brzezinski, O. Drize, N. Strauss, and T. Peretz. Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. Eur. J. Obstet. Gynecol. Reprod. Biol. 102:188-194 (2002).
35. J. R. Okita, P. J. Castle, and R. T. Okita. Characterization of cytochromes P450 in liver and kidney of rats treated with di-(2-ethylhexyl) phthalate. J. Biochem. Toxicol. 8:135-144 (1993).
36. I. H. Segel. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley and Sons, New York, 1975.
37. H. K. Crewe, S. W. Ellis, M. S. Lennard, and G. T. Tucker. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53:171-178 (1997).
38. C. K. Lim, Z. X. Yuan, J. H. Lamb, I. N. White, F. De Matteis, and L. L. Smith. A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis 15:589-593 (1994).
39. C. Mani, R. Pearce, A. Parkinson, and D. Kupfer. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis 15:2715-2720 (1994).
40. H. Doi, H. Iwasaki, Y. Masubuchi, R. Nishigaki, and T. Horie. Chemiluminescence associated with the oxidative metabolism of salicylic acid in rat liver microsomes. Chem. Biol. Interact. 140:109-119 (2002).
41. W. G. Chung, C. S. Park, H. K. Roh, W. K. Lee, and Y. N. Cha. Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn. J. Pharmacol. 84:213-220 (2000).
42. J. Schmider, D. J. Greenblatt, S. M. Fogelman, L. L. von Moltke, and R. I. Shader. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm. Drug Dispos. 18:227-240 (1997).
43. V. A. Eagling, J. F. Tjia, and D. J. Back. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br. J. Clin. Pharmacol. 45:107-114 (1998).
44. Y. Masubuchi, E. Masuda, and T. Horie. Multiple mechanisms in indomethacin-induced impairment of hepatic cytochrome P450 enzymes in rats. Gastroenterology 122:774-783 (2002).
45. K. Kobayashi, K. Urashima, N. Shimada, and K. Chiba. Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat. Drug Metab. Dispos. 31:833-836 (2003).
46. R. W. Wang, P. H. Kari, A. Y. Lu, P. E. Thomas, F. P. Guengerich, and K. P. Vyas. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys. 290:355-361 (1991).
47. Y. Ando, E. Fuse, and W. D. Figg. Thalidomide metabolism by the CYP2C subfamily. Clin. Cancer Res. 8:1964-1973 (2002).
48. M. G. Busby, A. R. Jeffcoat, L. T. Bloedon, M. A. Koch, T. Black, K. J. Dix, W. D. Heizer, B. F. Thomas, J. M. Hill, J. A. Crowell, and S. H. Zeisel. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am. J. Clin. Nutr. 75:126-136 (2002).
49. G. K. Poon, B. Walter, P. E. Lonning, M. N. Horton, and R. McCague. Identification of tamoxifen metabolites in human HepG2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab. Dispos. 23:377-382 (1995).